Skip to content
Clemedi
  • Home
  • Team
  • Tuberculini
  • Awards
  • News
  • Jobs
  • Twitter
  • Facebook
  • LinkedIn

Category: Press releases

Press Release
Dec 16, 2022

Press Release

English Version Schlieren, Switzerland, Munich, Germany, and Vienna, Austria, December 16, 2022 Clemedi AG concludes a license agreement for detecting latent tuberculosis with the Max Planck Society (MPG) and the Medical University of Vienna Clemedi aims to extend its tuberculosis product line to cover latent tuberculosis. This requires the ability to extract M. tuberculosis DNA…

read more
by Sebastian Dümckein Blog, Press releases0
Press Release
Oct 31, 2022

Press Release

Clemedi AG releases Tuberculini, its first molecular test for drug-resistant tuberculosis. Tuberculini is optimized to run on Thermo Fisher Scientific’s Ion GeneStudio S5™ System. Clemedi has developed a next-generation sequencing (NGS) based test called Tuberculini, that can recognise resistance to all major therapeutic agents used to treat tuberculosis. The assay – which received a CE-IVD…

read more
by Sebastian Dümckein Blog, Press releases0
  • Twitter
  • Facebook
  • LinkedIn
  • Terms and Conditions
  • Privacy Policy
© 2023 Clemedi. All rights reserved.
  • Twitter
  • Facebook
  • LinkedIn
Address:Wagistr. 12, 8952 Schlieren, Switzerland
Phone:+41 (0)43 229 38 21‬